Depakote FDA-Approved Indications
Depakote (divalproex sodium) is FDA-approved for three primary indications: epilepsy (complex partial seizures and absence seizures), acute manic or mixed episodes in bipolar disorder, and migraine prophylaxis. 11
FDA-Approved Indications
1. Epilepsy
- Monotherapy and adjunctive therapy for complex partial seizures
- Monotherapy and adjunctive therapy for simple and complex absence seizures
- Adjunctive therapy in patients with multiple seizure types that include absence seizures 11
Dosing for epilepsy:
- Complex partial seizures: Start at 10-15 mg/kg/day, increase weekly by 5-10 mg/kg/day
- Absence seizures: Start at 15 mg/kg/day, increase weekly by 5-10 mg/kg/day
- Maximum studied dose: 60 mg/kg/day 1
2. Bipolar Disorder
While the FDA label for Depakote Sprinkle Capsules specifically emphasizes epilepsy indications 11, other formulations of divalproex sodium are approved for acute manic or mixed episodes associated with bipolar disorder. Guidelines support its use as a mood stabilizer in pediatric and adult bipolar disorder 2, with evidence showing efficacy both as monotherapy and in combination with atypical antipsychotics.
3. Migraine Prophylaxis
Divalproex is FDA-approved for migraine prevention in adults. However, it is absolutely contraindicated for migraine prophylaxis in pregnant women and women of childbearing potential not using effective contraception due to severe teratogenic risks 1.
Critical Contraindications and Warnings
Absolute Contraindications:
- Hepatic disease or significant hepatic dysfunction
- Known mitochondrial disorders (POLG mutations)
- Suspected POLG-related disorder in children under 2 years
- Known hypersensitivity
- Urea cycle disorders
- Migraine prophylaxis in pregnant women or women of childbearing potential without effective contraception 1
Black Box Warnings:
- Hepatotoxicity: Fatal cases, especially in children under 2 years and those with mitochondrial disorders—requires baseline and frequent liver function monitoring 1
- Teratogenicity: Neural tube defects, major malformations, and decreased IQ following in utero exposure 1
- Pancreatitis: Including fatal hemorrhagic cases 1
Important Clinical Context from Guidelines
For pediatric migraine prevention: Guidelines note that placebo was as effective as studied medications in many trials, so clinicians should discuss this with families before initiating preventive therapy. When valproate is considered, teratogenic effects must be discussed, effective birth control advised, and folate supplementation recommended 3.
For pediatric bipolar disorder: Most youths require ongoing medication therapy to prevent relapse, with studies showing >90% relapse rates in non-compliant adolescents. Maintenance therapy should continue for 12-24 months after stabilization, with some requiring lifelong treatment 2.
Common Pitfalls
- Do not use once-daily dosing of standard delayed-release divalproex at high doses (≥2000 mg/day) due to excessive peak concentrations and risk of toxicity; extended-release formulation is required for once-daily dosing at these doses 4
- Monitor for DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms), though rare with valproate compared to aromatic anticonvulsants 5
- Storage matters: Sprinkle capsules show significant quality degradation with temperature/humidity exposure, potentially leading to increased gastric side effects and unpredictable absorption 6